,13,14 Our current study confirms the potential value of combined KRAS/TP53 mutational status as a prognostic biomarker in immunotherapy-treated patients and adds the prognostic value of TP53mut for combined chemoimmunotherapy in patients with KRASwt NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.